Category: Blog Posts

Genprex Honors June as Cancer Immunotherapy Month

Genprex is supporting The Society for Immunotherapy of Cancer (SITC) and the Cancer Research Institute’s Annual Cancer Immunotherapy Month in June.

Read More

Genprex’s Response to COVID-19 and its Business Operations

At Genprex, the health and well-being of the communities we serve, including those with cancer and diabetes, is our top priority.

Read More

Highlighting Genprex’s Medical Advisors on National Doctors’ Day

March 30 marks National Doctors’ Day, an annual holiday when we can all acknowledge and show appreciation for our physicians who help save lives everywhere.

Read More

The Power Behind Gene Therapy Drug Combinations

Genprex is harnessing the power of a combinational treatment approach to overcome treatment limitations and offer patients new treatment options.

Read More

Genprex is Pioneering the Use of Non-Viral Vectors in Gene Therapy

Genprex is once again leading the way in gene therapy and raising the standard in cancer treatment based upon its unique, proprietary technology platform that includes its non-viral vector nanoparticle delivery system.

Read More

Genprex’s Non-Viral Delivery System Once Again Ahead of Recent Industry Research

Researchers at Johns Hopkins Medicine recently published a study in Science Advances that introduces a non-viral delivery system for gene editing. Genprex has already treated more than 50 patients in Phase I and II clinical trials using its proprietary non-viral delivery system.

Read More

5 Things to Know about Lung Cancer Treatment

Cancer is a complex disease that can be difficult treat. Lung cancer specifically is the leading cause of cancer deaths worldwide, causing more deaths than breast, colon, kidney, liver or prostate cancers.

Genprex, a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients, is researching and developing therapies for the treatment of lung cancer….

Read More

A Deeper Dive into the Nature Research Scientific Report on TUSC2 and Triple-Negative Breast Cancer

Genprex recently announced that independent researchers found that company’s TUSC2 (tumor suppressor candidate 2) prevented tumor growth in triple-negative breast cancer (TNBC). These independent researchers have no affiliation with Genprex.

Genprex takes a deeper dive into the data of the study to provide analysis and a better understanding of what the study found and what it means for TUSC2….

Read More

Genprex is Defining a New Immunogene Therapy that Could Change the Course of Cancer

Genprex, a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients, is raising the standard in cancer treatment by developing what it calls an “immunogene therapy,” which harnesses the power of immunotherapy’s immunomodulation through the delivery of a gene therapy.

Gene therapies and immunotherapies are two different types of treatment….

Read More

Pfizer’s Half-Billion-Dollar Manufacturing Facility Demonstrates Commitment to Gene Therapy

Pfizer recently announced its plans to invest $500 million into its Sanford gene therapy manufacturing operations. This expansion would create 300 new jobs, and Pfizer’s biopharmaceuticals group president noted the company “passionately believes in gene therapy.”

This passion for gene therapy, which is seemingly shared with other large biopharma companies, is leading to substantial commitments of resources to gene therapy….

Read More